Evaluating the Safety and Efficacy of Inarigivir in Non-cirrhotic, Hepatitis B e Antigen-negative Subjects Infected With HBV Virus and Receiving or Stopping Treatment With a NUC Inhibitor

Hepatitis B Clinical Trial

Official title:

A Phase 2, Exploratory Study Evaluating the Safety and Antiviral Efficacy of Inarigivir Soproxil in Non-cirrhotic, Hepatitis B e Antigen-negative Subjects Infected With Chronic Hepatitis B Virus and Receiving or Stopping Treatment With a Nucleoside/Nucleotide Inhibitor

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT04023721
• Other study ID #: SBP-9200-HBV-206
• Status: Terminated
• Phase: Phase 2
• Start date: June 18, 2019
• Est. completion date: July 16, 2020

Study information

• Verified date: July 2020
• Source: Spring Bank Pharmaceuticals, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

An open-label, Phase 2, exploratory study to examine the safety and efficacy of inarigivir in non-cirrhotic, hepatitis B e antigen (HBeAg)-negative subjects with chronic HBV infection.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 64
• Est. completion date: July 16, 2020
• Est. primary completion date: July 16, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. HBV-infected male and female subjects aged 18 to 70 years, inclusive

2. Ultrasound, computed tomography (CT) scan, or magnetic resonance imaging (MRI) within 6 months of enrollment (Cohort 1) or randomization (Cohort 2) date with no evidence of cirrhosis or hepatocellular carcinoma (HCC)

3. Must be willing and able to comply with all study requirements

4. Have HBV DNA <LLOQ at Screening

5. ALT normal or, if elevated, <2× ULN with a documented etiology for elevation such as non-alcoholic fatty liver disease (NAFLD) confirmed by either ultrasound or controlled attenuation parameter (CAP) score >280 on elastography

6. Negative urine or serum pregnancy test (for women of childbearing potential) documented within the 24-hour period prior to the first dose of IP. If the urine pregnancy test is positive, a follow-up serum test is required for confirmation

7. Women of childbearing potential must agree to use a highly effective method of contraception throughout the study and for 3 months after discontinuing study treatment. Men with female partners who are of childbearing potential must agree that they or their partners will use a highly effective method of contraception throughout the study and for 3 months after discontinuing study treatment. Male subjects must not donate sperm throughout the study and for 3 months after discontinuing study treatment.

• Women of childbearing potential are sexually mature women who have not undergone bilateral tubal ligation, bilateral oophorectomy, or hysterectomy; or who have not been postmenopausal (ie, who have not menstruated at all) for at least 1 year.

• Highly effective methods of contraception are hormonal contraceptives (oral, injectable, patch, intrauterine devices), male partner sterilization, or total abstinence from heterosexual intercourse, when this is the preferred and usual lifestyle of the subject. Note: The double-barrier method (eg, synthetic condoms, diaphragm, or cervical cap with spermicidal foam, cream, or gel), periodic abstinence (such as calendar, symptothermal, post-ovulation), withdrawal (coitus interruptus), lactational amenorrhea method, and spermicide only are not acceptable as highly effective methods of contraception.

8. Must have the ability to understand and sign a written informed consent form (ICF); consent must be obtained prior to initiation of study procedures

In addition, subjects must meet the cohort-specific criteria listed below:

Cohort 1:

1. HBeAg-negative subjects on documented NUCs for =3 years with undetectable HBV DNA by polymerase chain reaction (PCR) documented at least annually over the last 2 years. NUCs can include tenofovir, entecavir, telbivudine, lamivudine, adefovir, and tenofovir-5TC.

2. HBsAg <1000 IU at Screening

3. Planning to discontinue NUC therapy

Cohort 2:

1. HBeAg-negative subjects on documented NUCs for =1 year with undetectable HBV DNA by PCR documented on at least 1 occasion in the last 6 months. NUCs can include tenofovir, entecavir, telbivudine, lamivudine, adefovir, and tenofovir-5TC.

2. Planning to continue NUC therapy

Exclusion Criteria:

1. Any prior liver biopsy evidence of metavir F3 or F4 disease

2. Any history of decompensation of liver disease including history of ascites, encephalopathy, or varices

3. Evidence of advanced fibrosis as defined by Fibroscan at the Screening Visit of

=8 kPa. If Fibroscan is not available, subjects with both a Fibrotest =0.65 and aspartate transaminase (AST):platelet ratio index (APRI) =1.0 are excluded (subjects will not be excluded if only 1 of the Fibrotest or APRI results is higher than allowed)

4. Laboratory parameters not within defined thresholds:

4.1 White blood cells <4000 cells/µL (<4.0×109/L) 4.2 Hemoglobin <11 g/dL (<110 g/L) for females, <13 g/dL (<130 g/L) for males 4.3 Platelets <130,000 per µL (<130×109/L) 4.4 Albumin <3.5 g/dL (<35 g/L) 4.5 International normalized ratio (INR) >1.5 4.6 Total bilirubin >1.2 mg/dL (>20.52 µmol/L) or alpha-fetoprotein (AFP) >50 ng/mL (>180.25 nmol/L). Subjects with an elevated indirect bilirubin and known Gilbert's disease can be included if direct bilirubin is within normal limits. Subjects with an AFP >50 ng/mL but <500 ng/mL can be included if CT scan or MRI performed within 3 months shows no evidence of HCC 4.7 Creatinine >1.2 mg/dL (>106.08 µmol/L) and creatinine clearance <50 mL/min (<0.83 L/s/m2)

5. Co-infection with hepatitis C virus (HCV), human immunodeficiency virus (HIV), or hepatitis D virus

6. Evidence or history of HCC

7. Malignancy within 5 years prior to Screening, with the exception of specific cancers that are cured by surgical resection (basal cell skin cancer, etc). Subjects under evaluation for possible malignancy are not eligible

8. Significant cardiovascular, pulmonary, or neurological disease

9. Received solid organ or bone marrow transplant

10. Received within 3 months of Screening or expected to receive prolonged therapy with immunomodulators (eg, corticosteroids) or biologics (eg, monoclonal antibody, IFN)

11. Subjects currently taking medication(s) that are transported through organic anion transporting polypeptide 1 (OATP1) including, but not limited to, atazanavir, rifampin, cyclosporine, eltrombopag, gemfibrozil, lopinavir/ritonavir, and saquinavir

12. Use of another investigational agent within 3 months of Screening

13. Current alcohol or substance abuse judged by the Investigator to potentially interfere with compliance

14. Females who are pregnant or may wish to become pregnant during the study

15. If the Investigator believes the prospective subject will not be able to comply with the requirements of the protocol and complete the study

16. Any medical condition that, in the opinion of the Investigator, could interfere with evaluation of the study objectives or safety of the subjects

Related Conditions & MeSH terms

• HBV
• Hepatitis
• Hepatitis A
• Hepatitis B
• Hepatitis B, Chronic

Intervention

Drug:
• Inarigivir soproxil
Inarigivir soproxil 200 mg tablets
• Nucleoside/nucleotide (NUC) analogue inhibitors
Continuation of prestudy NUC therapy

Locations

Country	Name	City	State
Canada	University of Calgary	Calgary	Alberta
Canada	Toronto General Hospital	Toronto	Ontario
Canada	Toronto Liver Center	Toronto	Ontario
Canada	GI Research Institute	Vancouver	British Columbia
Canada	LAIR Centre	Vancouver	British Columbia
United Kingdom	Barts Health NHS Trust	London	England
United Kingdom	King's College Hospital NHS Foundation Trust	London	England

Sponsors (2)

Lead Sponsor	Collaborator
Spring Bank Pharmaceuticals, Inc.	PRA Health Sciences

Countries where clinical trial is conducted

Canada,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportion of subjects reporting an adverse event, clinically significant adverse event, or laboratory abnormality	Proportion of subjects in Cohort 1 and 2 reporting an adverse event, clinically significant adverse event, or laboratory abnormality from start to end of treatment, and 30 days after stopping treatment	28 to 52 weeks
Primary	Change in quantitative HBsAg (Cohort 1)	Reduction in quantitative hepatitis B surface antigen (HBsAg) by >0.3 log10 from Baseline to Week 24 of subjects in Cohort 1	Baseline to Week 24
Primary	Change in the percentage of subjects with loss of HBsAg (Cohort 1)	Percentage of subjects in Cohort 1 with loss of hepatitis B surface antigen (HBsAg) from Baseline to Weeks 24 and 48	Baseline to Weeks 24 and Week 48
Primary	Percentage of subjects with ALT flares (Cohort 1)	Percentage of subjects in Cohort 1 with alanine transaminase (ALT) flares, defined as ALT >200 IU or hepatitis B virus (HBV) DNA >20,000 IU	96 Weeks
Primary	Percentage of subjects with suppression of HBV DNA <2000 IU/L (Cohort 1)	Percentage of subjects in Cohort 1 with suppression of hepatitis B virus (HBV) DNA <2000 IU/L at Weeks 24 and 48	Weeks 24
Primary	Percentage of subjects with suppression of HBV DNA <2000 IU/L (Cohort 1)	Percentage of subjects in Cohort 1 with suppression of hepatitis B virus (HBV) DNA <2000 IU/L at Weeks 24 and 48	Weeks 48
Primary	Percentage of subjects with ALT <40 IU/L (Cohort 1)	Percentage of subjects in Cohort 1 with alanine transaminase (ALT) <40 IU/L at Weeks 24, 48, 72, and 96	Weeks 24
Primary	Percentage of subjects with ALT <40 IU/L (Cohort 1)	Percentage of subjects in Cohort 1 with alanine transaminase (ALT) <40 IU/L at Weeks 24, 48, 72, and 96	Weeks 48
Primary	Percentage of subjects with ALT <40 IU/L (Cohort 1)	Percentage of subjects in Cohort 1 with alanine transaminase (ALT) <40 IU/L at Weeks 24, 48, 72, and 96	Weeks 72
Primary	Percentage of subjects with ALT <40 IU/L (Cohort 1)	Percentage of subjects in Cohort 1 with alanine transaminase (ALT) <40 IU/L at Weeks 24, 48, 72, and 96	Weeks 96
Primary	Percentage of subjects who lose HBsAg (Cohort 1)	Percentage of subjects in Cohort 1 who lose hepatitis B surface antigen (HBsAg) at Weeks 72 and 96	Weeks 72
Primary	Percentage of subjects who lose HBsAg (Cohort 1)	Percentage of subjects in Cohort 1 who lose hepatitis B surface antigen (HBsAg) at Weeks 72 and 96	Weeks 96
Primary	Percentage of subjects with suppression of HBV DNA <2000 IU/L (Cohort 2)	Percentage of subjects in Cohort 2 with suppression of hepatitis B virus (HBV) DNA <2000 IU/L at Weeks 72 and 96 (off inarigivir treatment)	Weeks 72
Primary	Percentage of subjects with suppression of HBV DNA <2000 IU/L (Cohort 2)	Percentage of subjects in Cohort 2 with suppression of hepatitis B virus (HBV) DNA <2000 IU/L at Weeks 72 and 96 (off inarigivir treatment)	Weeks 96
Primary	Percentage of subjects with ALT <40 IU/L (Cohort 2 )	Percentage of subjects in Cohort 2 with alanine transaminase (ALT) <40 IU/L at Weeks 72 and 96 (off inarigivir treatment)	Weeks 72
Primary	Percentage of subjects with ALT <40 IU/L (Cohort 2 )	Percentage of subjects in Cohort 2 with alanine transaminase (ALT) <40 IU/L at Weeks 72 and 96 (off inarigivir treatment)	Weeks 96
Primary	Percentage of subjects with HBsAg <1000 IU (Cohort 2)	Percentage of subjects in Cohort 2 with alanine transaminase (ALT) <40 IU/L at Weeks 72 and 96 (off inarigivir treatment)	Weeks 72
Primary	Percentage of subjects with HBsAg <1000 IU (Cohort 2)	Percentage of subjects in Cohort 2 with alanine transaminase (ALT) <40 IU/L at Weeks 72 and 96 (off inarigivir treatment)	Weeks 96
Secondary	Change in serum levels of IFN-a, IFN-?, TNF, IL-6, IL-10, and IP-10	Fold change from Baseline in markers of innate immunity in serum of IFN-a, IFN-?, TNF, IL-6, IL-10, and IP-10 in subjects in Cohort 1 and 2	Baseline to Week 96 (100 weeks)
Secondary	Percentage of subjects with HBsAg decline >0.3 log10 (Cohort 2)	Percentage of subjects in Cohort 2 with hepatitis B surface antigen (HBsAg) decline >0.3 log10 at Weeks 12, 24, 48, 72, and 96	Weeks 12, 24, 48, 72, and 96
Secondary	Percentage of subjects with HBsAg decline >0.5 log10 (Cohort 2)	Percentage of subjects in Cohort 2 with hepatitis B surface antigen (HBsAg) decline >0.5 log10 at Weeks 12, 24, 48, 72, and 96	Weeks 12, 24, 48, 72, and 96
Secondary	Percentage of subjects with HBsAg loss (Cohort 2)	Percentage of subjects in Cohort 2 with hepatitis B surface antigen (HBsAg) loss at Weeks 24, 48, 72, and 96	Weeks 24, 48, 72, and 96
Secondary	Percentage of subjects with undetectable HBV DNA (Cohort 2)	Percentage of subjects in Cohort 2 with undetectable hepatitis B virus (HBV) DNA at Weeks 24, 48, 72, and 96	Weeks 24, 48, 72, and 96
Secondary	Percentage of subjects who suppress HBsAg <100 IU (Cohort 2)	Percentage of subjects in Cohort 2 who suppress hepatitis B surface antigen (HBsAg) <100 IU at Weeks 24, 48, 72, and 96	Weeks 24, 48, 72, and 96
Secondary	Change in serum HBV DNA, HBsAg, and HBV RNA in log10 IU/mL (Cohort 2)	Change in serum hepatitis B virus (HBV) DNA, hepatitis B surface antigen (HBsAg), and HBV RNA in log10 IU/mL from Baseline to Weeks 12, 24, 48, 72, and 96 for subjects in Cohort 2	Baseline to Week 96 (100 weeks)